Truist Financial
RARE icon

Truist Financial’s Ultragenyx Pharmaceutical RARE Stock Holding History

Truist Financial’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-5,503
Closed -$200K – 2780
2025
Q2 		$200K Sell
5,503
-4,080
-43% -$147K ﹤0.01% 2424
2025
Q1 		$347K Sell
9,583
-1,103
-10% -$45.9K ﹤0.01% 2070
2024
Q4 		$450K Sell
10,686
-1,615
-13% -$80.1K ﹤0.01% 1949
2024
Q3 		$683K Buy
12,301
+2,510
+26% +$128K ﹤0.01% 1707
2024
Q2 		$402K Sell
9,791
-319
-3% -$13.6K ﹤0.01% 2106
2024
Q1 		$472K Sell
10,110
-1,613
-14% -$76.1K ﹤0.01% 1994
2023
Q4 		$561K Sell
11,723
-7,291
-38% -$283K ﹤0.01% 1901
2023
Q3 		$678K Sell
19,014
-599
-3% -$23.7K ﹤0.01% 1753
2023
Q2 		$905K Buy
19,613
+4,726
+32% +$219K ﹤0.01% 1634
2023
Q1 		$597K Buy
14,887
+655
+5% +$28.1K ﹤0.01% 1867
2022
Q4 		$659K Buy
14,232
+2,710
+24% +$107K ﹤0.01% 1774
2022
Q3 		$477K Buy
11,522
+3,883
+51% +$200K ﹤0.01% 1842
2022
Q2 		$456K Sell
7,639
-65
-0.8% -$4K ﹤0.01% 1961
2022
Q1 		$559K Buy
7,704
+1,318
+21% +$91.7K ﹤0.01% 1946
2021
Q4 		$537K Buy
6,386
+7
+0.1% +$570 ﹤0.01% 1974
2021
Q3 		$575K Buy
6,379
+195
+3% +$17.6K ﹤0.01% 1921
2021
Q2 		$590K Sell
6,184
-323
-5% -$33.7K ﹤0.01% 1951
2021
Q1 		$741K Buy
6,507
+391
+6% +$53.2K ﹤0.01% 1758
2020
Q4 		$846K Buy
6,116
+863
+16% +$102K ﹤0.01% 1566
2020
Q3 		$432K Buy
5,253
+654
+14% +$54.2K ﹤0.01% 1801
2020
Q2 		$360K Buy
+4,599
New +$304K ﹤0.01% 1820

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Truist Financial's RARE Position: Q3 2025 in Review

Truist Financial sold out of Ultragenyx Pharmaceutical (RARE) in Q3 2025, closing a stake of 5,503 shares — an estimated $200K sold.

Truist Financial first reported a position in RARE in Q2 2020 and held it in 21 quarters. The position peaked at $905K in Q2 2023. 302 funds tracked by Wall St. Rank hold RARE as of Q3 2025.

  • Truist Financial reported no remaining Ultragenyx Pharmaceutical position as of Q3 2025 after selling out during the quarter.
  • Truist Financial sold 5,503 Ultragenyx Pharmaceutical shares in Q3 2025, an estimated $200K.
  • Truist Financial first reported a position in Ultragenyx Pharmaceutical in Q2 2020 and held it in 21 quarters.
  • Truist Financial's Ultragenyx Pharmaceutical position peaked at $905K in Q2 2023.
  • 302 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2025.

Based on Truist Financial's 13F filing for Q3 2025, filed 3 Nov 2025.